Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toward Precision Phenotyping of Multiple Sclerosis.
Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Pitt D, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 30;9(6):e200025. doi: 10.1212/NXI.0000000000200025. Print 2022 Nov. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36041861 Free PMC article. Review.
Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing.
Rempe T, Wang Q, Wu Q, Ballur Narayana Reddy V, Newcomer Z, Miravalle A, Mao-Draayer Y. Rempe T, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 20;7(3):e709. doi: 10.1212/NXI.0000000000000709. Print 2020 May 4. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32198230 Free PMC article. No abstract available.
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Longbrake EE, et al. Mult Scler. 2021 May;27(6):883-894. doi: 10.1177/1352458520937282. Epub 2020 Jul 27. Mult Scler. 2021. PMID: 32716690 Free PMC article. Clinical Trial.
Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
Abboud H, Salazar-Camelo A, George N, Planchon SM, Matiello M, Mealy MA, Goodman A; On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium. Abboud H, et al. J Neurol. 2022 Apr;269(4):1786-1801. doi: 10.1007/s00415-021-10783-4. Epub 2021 Sep 5. J Neurol. 2022. PMID: 34482456 Free PMC article. Review.
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis.
Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, Kasper IR, Oliver B, Mielcarz DW, Kasper LH. Fadul CE, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096. doi: 10.1212/NXI.0000000000001096. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34654708 Free PMC article. Clinical Trial.
Current and Future Biomarkers in Multiple Sclerosis.
Yang J, Hamade M, Wu Q, Wang Q, Axtell R, Giri S, Mao-Draayer Y. Yang J, et al. Int J Mol Sci. 2022 May 24;23(11):5877. doi: 10.3390/ijms23115877. Int J Mol Sci. 2022. PMID: 35682558 Free PMC article. Review.
75 results